Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.40 |
| ▸ | CNR1 | P21554 | 10/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21784451 | 0.98 | CYP2D6 (0.41) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL22585255 | 0.93 | CYP2D6 (0.41) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL24871950 | 0.87 | FAAH (0.40) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL18557088 | 0.87 | FAAH (0.40) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL24872011 | 0.87 | FAAH (0.40) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL22828519 | 0.87 | FAAH (0.40) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL21370103 | 0.86 | CYP19A1 (0.39) | FAAHCYP2D6CYP19A1CYP3A4 | |
| SCHEMBL18612676 | 0.85 | FAAH (0.39) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL22964913 | 0.85 | FAAH (0.39) | CNR2CNR1FAAHCYP2D6CYP19A1 | |
| SCHEMBL18415044 | 0.84 | FAAH (0.38) | CNR2CNR1FAAHCYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | MITSUI CHEMICALS AGRO, INC. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-20200045968-A1 | PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | MITSUI CHEMICALS AGRO, INC. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253027-B2 | Aryl lactam kinase inhibitors | AAK1, ADCK1, ANKK1 | CNR2 4439/4885CNR1 4029/4885FAAH 2443/4885 |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | CNR2 2172/4885CNR1 2306/4885FAAH 1125/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | CNR2 2172/4885CNR1 2306/4885FAAH 1125/4885 |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | PNPO, CYP4X1, PDXK | CNR2 2191/4885CNR1 1509/4885FAAH 2993/4885 |
| US-20200045968-A1 | PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | PNPO, CYP4X1, PDXK | CNR2 2191/4885CNR1 1509/4885FAAH 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.